PPBT stock forecast, quote, news & analysis
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals... Show more
Why Purple Biotech (PPBT) Stock Is Up +73% in the Last 30 Days
Key Takeaways
- Purple Biotech (PPBT) has climbed roughly 73% over the trailing 30 days, from about $1.47 in early August to around $2.55.
- A U.S. patent Notice of Allowance covering tri-specific antibody designs from its CAPTN-3 platform was the primary catalyst, triggering unusually heavy trading volume.
- New preclinical data on lead candidate IM1240 and a manufacturing milestone have reinforced investor interest in the platform.
- The stock remains far below year-ago levels and is still down over the trailing quarter despite the sharp rebound.
- Purple Biotech is pre-revenue, with roughly $6.1 million in cash as of June 30, 2026, funding operations into mid-2027.
Purple Biotech (PPBT) Company Overview and Market Position
Purple Biotech Ltd. is a clinical-stage oncology company headquartered in Rehovot, Israel, developing next-generation immunotherapies designed to overcome tumor immune evasion and drug resistance. Its lead program, CAPTN-3, is a platform of "capped" tri-specific antibodies that bind tumor cells while engaging both T cells and natural killer (NK) cells. The lead candidate, IM1240, is advancing toward clinical development, with IM1305 in preclinical studies.
The pipeline also includes CM24, a CEACAM1-blocking antibody that demonstrated improved outcomes across efficacy endpoints in a Phase 2 pancreatic cancer study, and NT219, a dual IRS1/2 and STAT3 inhibitor in Phase 2 for recurrent or metastatic head and neck cancer. As a pre-revenue micro-cap, Purple Biotech is a high-risk, high-reward story in which pipeline science — and the company's ability to fund it — drives investor attention.
Purple Biotech (PPBT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PPBT shares have advanced from roughly $1.47 to approximately $2.55, a gain of about 73%. The move was concentrated in a few high-volume sessions driven by company-specific news rather than a gradual grind higher.
The picture over the full quarter is more mixed. From roughly $2.95 in early June, shares declined to about $1.66 by the start of September — a drop of approximately 44% — before the recent rally pared those losses. In other words, the 30-day advance represents a sharp, news-driven rebound within a broader multi-month downtrend, and the stock remains well below where it traded a year ago.
What Drove PPBT Stock Price in the Last 30 Days
The dominant catalyst was a patent update. The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent tied to the CAPTN-3 platform covering tri-specific antibody designs and their uses. Management described the allowance as reinforcing protection for the platform's modular design, which allows the company to swap tumor-targeting and functional components to develop new multispecific candidates. The announcement drove unusually heavy volume — tens of millions of shares changed hands versus a typical average in the tens of thousands.
Supporting the rally, Purple Biotech reported second-quarter 2026 results on August 7 that highlighted new preclinical data for IM1240 and progress across the CAPTN-3 platform. The company separately announced a manufacturing milestone for IM1240. On the analyst side, H.C. Wainwright maintained a Buy rating but lowered its price target from $30 to $17, citing a low cash balance and higher operating expenses. The combination of positive pipeline news, a thin float, and speculative momentum amplified the upside move.
What Drove PPBT Stock Performance Over the Last Quarter
The broader quarterly trend has been shaped by structural and balance-sheet pressures rather than pipeline news. In early March 2026, Purple Biotech completed a one-for-ten reverse split of its American Depositary Shares — implemented as an ADS ratio change — to regain compliance with Nasdaq's $1.00 minimum bid price requirement. While such actions are technical adjustments that do not change underlying value, they often accompany stocks under listing or funding pressure.
Through the quarter, the shares continued to slide as investors weighed a shrinking cash position and the likelihood of future dilution. The company reported roughly $6.1 million in cash as of June 30, 2026, which it expects to fund operations only into mid-2027. That financing overhang, combined with broader weakness across small- and micro-cap pre-revenue biotech names, kept the stock in a downtrend until the late-quarter patent and data catalysts sparked a rebound.
Trending AI Robots
For investors seeking a systematic view of momentum across the market, Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, holding timeframe, and performance metrics, so the page serves as a way to compare different approaches rather than a single recommendation. Exploring the section can help traders identify data-driven patterns and consider how algorithmic signals align with their own research.
PPBT Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape Purple Biotech's stock going forward. The most important is advancement of IM1240 toward a first-in-human Phase 1 trial, which management has targeted for 2027 and made contingent on securing a partnership or additional financing. Additional preclinical data readouts from IM1240 and IM1305 are expected through 2026 and could serve as recurring catalysts.
Investors should also monitor the company's cash runway and any capital-raising activity, given the roughly $6.1 million cash balance. Maintaining Nasdaq listing compliance, the formal issuance of the newly allowed patent, and the next quarterly earnings report remain key milestones. Because Purple Biotech is pre-revenue, clinical, regulatory, and financing outcomes — rather than sales or earnings growth — will continue to drive valuation. As with any early-stage biotech, these developments carry substantial uncertainty and should be evaluated within a broader, diversified investment approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PPBT's Stochastic Oscillator sits in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
PPBT moved above its 50-day moving average on August 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PPBT crossed bullishly above the 50-day moving average on August 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 57%.
Following a +5.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 165 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 66 of 83 cases where PPBT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for PPBT moved out of overbought territory on September 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 11 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PPBT broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.233) is normal, around the industry mean (19.994). P/E Ratio (0.004) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology